Program
veverimer
Also written as “TRC101” and “Veverimer”.
Its studies are mostly in Acidosis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tricida | 40 open or running | phase 3since Oct 11, 2017 | Jun 14, 2016 | none ahead |
| Renibus Therapeutics | 11 open or running | phase 3since Nov 25, 2025 | Nov 25, 2025 | Jun 2027phase 3 · NCT07355062 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 14, 2016First study: phase 2 study in AcidosisNew to TricidaTricida · NCT02809183 · 135 enrolled · Bulgaria, Georgia
- Oct 11, 2017Phase 3 study in AcidosisTricida · NCT03317444 · 217 enrolled · United States, Bulgaria, Croatia and more
- Dec 28, 2017Phase 3 study in AcidosisTricida · NCT03390842 · 196 enrolled · United States, Bulgaria, Georgia and more
- Oct 11, 2018Phase 3 study in AcidosisTricida · NCT03710291 · 1,480 enrolled · United States, Albania, Argentina and more
- Nov 25, 2025Renibus Therapeutics's first study: phase 3 study in AcidosisNew to Renibus TherapeuticsRenibus Therapeutics · NCT07355062 · 150 planned · United States
Ahead
- Jun 2027Primary completion: phase 3 study in AcidosisRenibus Therapeutics · NCT07355062
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07355062Acidosis · United States | 3 | Recruiting | Renibus Therapeutics | Jun 2027 | 150 |
| NCT03710291Acidosis · United States, Albania, Argentina and more | 3 | Terminated | Tricida | Aug 23, 2022 | 1,480 |
| NCT03390842Acidosis · United States, Bulgaria, Georgia and more | 3 | Completed | Tricida | Feb 22, 2019 | 196 |
| NCT03317444Acidosis · United States, Bulgaria, Croatia and more | 3 | Completed | Tricida | May 4, 2018 | 217 |
| NCT02809183Acidosis · Bulgaria, Georgia | 2 | Completed | Tricida | Nov 2016 | 135 |
How it is read
Names in the registry
- “TRC101”, 4 entries
- “Veverimer”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.